Zobrazeno 1 - 10
of 93
pro vyhledávání: '"Hua Naranmandura"'
Autor:
Huafeng Wang, Chang Yang, Ting Shi, Yi Zhang, Jiejing Qian, Yungui Wang, Yongxian Hu, Liping Mao, Xiujin Ye, Fang Liu, Zhenfang Xi, Lihong Shou, Caiyun Fu, Hua Naranmandura, Jie Jin, Hong-Hu Zhu
Publikováno v:
Blood Cancer Journal, Vol 12, Iss 1, Pp 1-4 (2022)
Externí odkaz:
https://doaj.org/article/65a3742565e74b65baa7345580beda80
Autor:
Yasen Maimaitiyiming, Tao Yang, Qian Qian Wang, Yan Feng, Zhi Chen, Mikael Björklund, Fudi Wang, Chonggao Hu, Chih-Hung Hsu, Hua Naranmandura
Publikováno v:
Research, Vol 2022 (2022)
Despite extensive efforts, COVID-19 pandemic caused by the SARS-CoV-2 virus is still at large. Vaccination is an effective approach to curb virus spread, but several variants (e.g., delta, delta plus, omicron, and IHU) appear to weaken or possibly es
Externí odkaz:
https://doaj.org/article/3fa9fcaf20c6481a94232b610a9dd34e
Publikováno v:
Bioengineering, Vol 9, Iss 11, p 635 (2022)
Hematologic malignancies, including leukemia, lymphoma, myeloproliferative disorder and plasma cell neoplasia, are genetically heterogeneous and characterized by an uncontrolled proliferation of their corresponding cell lineages in the bone marrow, p
Externí odkaz:
https://doaj.org/article/b583cd8df6b94ccdb7d541c3f918e83a
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 8, p 4442 (2022)
The coding regions account for only a small part of the human genome, and the remaining vast majority of the regions generate large amounts of non-coding RNAs. Although non-coding RNAs do not code for any protein, they are suggested to work as either
Externí odkaz:
https://doaj.org/article/be97aa4e159d48c49b9dff9c5cbf2de3
Autor:
Yu Han Jiang, Ye Jia Chen, Chao Wang, Yong Fei Lan, Chang Yang, Qian Qian Wang, Liaqat Hussain, Yasen Maimaitiying, Islam Khairul, Hua Naranmandura
Publikováno v:
International Journal of Molecular Sciences, Vol 18, Iss 2, p 247 (2017)
Arsenic trioxide (As2O3) has recently become one of the most effective drugs for treatment of patient with acute promyelocytic leukemia (APL), and its molecular mechanism has also been largely investigated. However, it has been reported that As2O3 re
Externí odkaz:
https://doaj.org/article/319e227c65434193aec943595b1c728c
Publikováno v:
PLoS ONE, Vol 7, Iss 6, p e38495 (2012)
Cytochrome P450 oxidoreductase (POR) is known as the sole electron donor in the metabolism of drugs by cytochrome P450 (CYP) enzymes in human. However, little is known about the effect of polymorphic variants of POR on drug metabolic activities of CY
Externí odkaz:
https://doaj.org/article/352a681748d34288a30167ed94bf5f52
Publikováno v:
Expert Opinion on Drug Discovery. 18:247-268
Hyperthermia promotes degradation of the acute promyelocytic leukemia driver oncoprotein ZBTB16/RARα
Autor:
Qian-qian Wang, Liaqat Hussain, Pei-han Yu, Chang Yang, Chen-ying Zhu, Ya-fang Ma, Si-chun Wang, Tao Yang, Yuan-yuan Kang, Wen-juan Yu, Yasen Maimaitiyiming, Hua Naranmandura
Publikováno v:
Acta Pharmacologica Sinica. 44:822-831
The acute promyelocytic leukemia (APL) driver ZBTB16/RARα is generated by the t(11;17) (q23;q21) chromosomal translocation, which is resistant to combined treatment of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) or conventional chemoth
Publikováno v:
The Natural Products Journal. 12
Abstract: Metals occur naturally in soil and many kinds of rocks, particularly in minerals and ores, which also play a vital role in living systems such as plants and animals. Over the large time scale, metal evolution from toxins to drugs has achiev
Autor:
Hong-Hu Zhu, Yungui Wang, Fang Liu, Caiyun Fu, Ting Shi, Liping Mao, Chang Yang, Zhenfang Xi, Lihong Shou, Yongxian Hu, Xiujin Ye, Hua Naranmandura, Jie Jin, Huafeng Wang, Jiejing Qian, Yi Zhang
Publikováno v:
Blood Cancer Journal, Vol 12, Iss 1, Pp 1-4 (2022)
Blood Cancer Journal
Blood Cancer Journal
The outcome of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) have greatly improved in tyrosine kinase inhibitors (TKIs) era and is just moving to a chemo-free era using dasatinib and blinatumomab (Foà R, N Engl J Med. 2020;